The failure of Incyte's epacadostat last year cooled enthusiasm for cancer immunotherapies designed to build upon the strong foundation laid by the PD-(L)1 inhibitor class, now led by Merck & Co.'s Keytruda.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,